Naloxone Hydrochloride Mercury Pharmaceuticals Limited

Naloxone Hydrochloride, the active ingredient in Naloxone Hydrochloride Mercury Pharmaceuticals Limited, is an opioid antagonist presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It rapidly reverses opioid‑induced respiratory depression and sedation in patients experiencing an acute opioid overdose.

GNH USA supplies Naloxone Hydrochloride Mercury Pharmaceuticals Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable global logistics for this critical emergency medication.

Naloxone Hydrochloride is an opioid antagonist that counteracts the effects of opioid drugs across the central nervous system.

Acute opioid overdose: rapidly restores normal breathing and consciousness in individuals who have received a potentially lethal dose of an opioid. Opioid‑induced respiratory depression: reverses suppressed respiratory drive caused by opioids, improving oxygenation and ventilation. Opioid analgesia reversal: terminates opioid‑mediated pain relief when rapid discontinuation of analgesia is required, such as before emergency procedures.

Adverse reactions may occur following administration of Naloxone Hydrochloride.

Common Side Effects: - Nausea or vomiting - Sweating or diaphoresis - Tachycardia or palpitations - Hypertension or elevated blood pressure - Anxiety or agitation - Headache

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Cardiac arrhythmias, including ventricular tachycardia - Seizures or convulsions - Pulmonary edema or acute respiratory distress - Anaphylactic or severe allergic reactions - Local injection site necrosis or severe pain

Naloxone Hydrochloride should be used with careful clinical monitoring.

Assess airway and breathing: ensure adequate ventilation before and after administration. Monitor cardiovascular status: watch for hypertension, tachycardia, or arrhythmias. Use with caution in patients with cardiovascular disease: increased risk of hemodynamic changes. Avoid in patients with known hypersensitivity to naloxone or its excipients. Pregnancy and lactation: administer only if the expected benefit outweighs potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone Hydrochloride may interact with other medications affecting the central nervous or cardiovascular systems.

Major Interactions (Avoid): - Concurrent use of potent opioid agonists (e.g., fentanyl) may precipitate severe withdrawal. - Combined use with mixed agonist‑antagonist opioids (e.g., buprenorphine) can cause unpredictable opioid effects. - Use with monoamine oxidase inhibitors may increase the risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Co‑administration of adrenergic agents may augment hypertension. - Use with other central nervous system stimulants may increase anxiety or agitation.